Identification

Name
Aceclofenac
Accession Number
DB06736
Type
Small Molecule
Groups
Approved, Investigational
Description

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [2, 3, 5]. Aceclofenac potently inhibits the cyclo-oxygenase enzyme (COX) that is involved in the synthesis of prostaglandins, which are inflammatory mediators that cause pain, swelling, inflammation, and fever. It is orally administered for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Aceclofenac belongs to BCS Class II as it possesses poor aqueous solubility [2]. It displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and related conditions, the loss of articular cartilage in the area causes joint pain, tenderness, stiffness, crepitus, and local inflammation [1]. Aceclofenac is also reported to be effective in other painful conditions such as dental and gynaecological conditions [7]. In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, Diclofenac, via chemical modification in effort to improve the gastrointestinal tolerability of the drug. It is a more commonly prescribed drug in Europe.

Structure
Thumb
Synonyms
  • 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester
  • 2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid
  • 2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acid
  • Aceclofenac
  • acéclofénac
  • Aceclofenac betadex
  • Aceclofenaco
  • Aceclofenacum
  • glycolic acid [o-(2,6-dichloroanilino)phenyl]acetate ester
International/Other Brands
Cincofen / Clanza / Hifenac
Categories
UNII
RPK779R03H
CAS number
89796-99-6
Weight
Average: 354.18
Monoisotopic: 353.0221633
Chemical Formula
C16H13Cl2NO4
InChI Key
MNIPYSSQXLZQLJ-UHFFFAOYSA-N
InChI
InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
IUPAC Name
2-[(2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetyl)oxy]acetic acid
SMILES
OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl

Pharmacology

Indication

Indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Structured Indications
Not Available
Pharmacodynamics

Aceclofenac is a NSAID that inhibits both isoforms of COX enzyme, a key enzyme involved in the inflammatory cascade. COX-1 enzyme is a constitutive enzyme involved in prostacyclin production and protective functions of gastric mucosa whereas COX-2 is an inducible enzyme involved in the production of inflammatory mediators in response to inflammatory stimuli. Aceclofenac displays more selectivity towards COX-2 (IC50 of 0.77uM) than COX-1 (IC50 of >100uM), which promotes its gastric tolerance compared to other NSAIDs. The primary metabolite, 4'-hydroxyaceclofenac, also minimally inhibits COX-2 with IC50 value of 36uM [2]. Although the mode of action of aceclofenac is thought to mainly arise from the inhibition of synthesis of prostaglandins (PGE2), aceclofenac also inhibits the production of inflammatory cytokines, interleukins (IL-1β, IL-6), and tumor necrosis factors (TNF) [1, 2]. It is also reported that aceclofenac also affects the cell adhesion molecules from neutrophils [A19763]. Aceclofenac also targets the synthesis of glycosaminoglycan and mediates chrondroprotective effects [1].

Mechanism of action

Through COX-2 inhibition, aceclofenac downregulates the production of various inflammatory mediators including prostaglandin E2 (PGE2), IL-1β, and TNF from the arachidonic acid (AA) pathway. Inhibition of IL-6 is thought to be mediated by diclofenac converted from aceclofenac [6]. Suppressed action of inflammatory cytokines decreases the production of reactive oxygen species. Aceclofenac is shown to decreased production of nitrous oxide in human articular chondrocytes [2]. In addition, aceclofenac interferes with neutrophil adhesion to endothelium by decreasing the expression of L-selectin (CD62L), which is a cell adhesion molecule expressed on lymphocytes [8]. Aceclofenac is proposed to stimulate the synthesis of glycosaminoglycan in human osteoarthritic cartilage which may be mediated through its inhibitory action on IL-1 production and activity [1]. The chrondroprotective effects are generated by 4'-hydroxyaceclofenac which suppresses IL-1 mediated production of promatrix metalloproteinase-1 and metalloproteinase-3 and interferes with the release of proteoglycan from chrondrocytes [1, 2, 7].

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma [11]. There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses [2].

Volume of distribution

The volume of distribution is approximately 25 L [11].

Protein binding

It is reported to be highly protein-bound (>99%) [11].

Metabolism

4'-hydroxyaceclofenac is the main metabolite detected in plasma however other minor metabolites include diclofenac, 5-hydroxyaceclofenac, 5-hydroxydiclofenac, and 4'-hydroxydiclofenac [2]. It is probable that the metabolism of aceclofenac is mediated by CYP2C9 [9].

Route of elimination

The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug [2]. Approximately two thirds of the administered dose is excreted via the urine, mainly as glucuronidated and hydroxylated forms of aceclofenac [11]. About 20% of the dose is excreted into feces [6].

Half life

The mean plasma elimination half-life is approximately 4 hours [11].

Clearance

The mean clearance rate is approximately 5 L/h [9].

Toxicity

Some common adverse effects include gastro-intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber, urticaria, symptoms of enuresis, headache, dizziness, and drowsiness [12]. Oral LD50 value in rats is 130 mg/kg [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabAceclofenac may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Aceclofenac can be decreased when combined with Abiraterone.Approved
AcebutololAceclofenac may decrease the antihypertensive activities of Acebutolol.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Acemetacin.Approved
AcenocoumarolAceclofenac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aceclofenac.Approved, Vet Approved
AclarubicinAceclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Aceclofenac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.Approved
AliskirenAceclofenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alminoprofen.Experimental
AlprenololAceclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Aceclofenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Amcinonide.Approved
AmikacinAceclofenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAceclofenac may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Aceclofenac can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinAceclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAceclofenac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aceclofenac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Anisodamine.Investigational
annamycinAceclofenac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aceclofenac.Approved
Antithrombin III humanAceclofenac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanAceclofenac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Apocynin.Investigational
ApramycinAceclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Aceclofenac.Approved, Investigational
AprepitantThe metabolism of Aceclofenac can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinAceclofenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAceclofenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAceclofenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAceclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Atamestane.Investigational
AtenololAceclofenac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Aceclofenac.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Aceclofenac.Approved
BalsalazideAceclofenac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAceclofenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAceclofenac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAceclofenac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Aceclofenac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Aceclofenac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aceclofenac.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aceclofenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betamethasone.Approved, Vet Approved
BetaxololAceclofenac may decrease the antihypertensive activities of Betaxolol.Approved
BevantololAceclofenac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
BisoprololAceclofenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAceclofenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAceclofenac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aceclofenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bucillamine.Investigational
BucindololAceclofenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bufexamac.Experimental
BufuralolAceclofenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bumadizone.Experimental
BumetanideAceclofenac may decrease the diuretic activities of Bumetanide.Approved
BupranololAceclofenac may decrease the antihypertensive activities of Bupranolol.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Aceclofenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Aceclofenac.Experimental
CapecitabineThe metabolism of Aceclofenac can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Aceclofenac.Approved
CarbamazepineThe metabolism of Aceclofenac can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Aceclofenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Aceclofenac.Approved, Vet Approved, Withdrawn
CarteololAceclofenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAceclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aceclofenac.Experimental
CeliprololAceclofenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Aceclofenac can be increased when it is combined with Ceritinib.Approved
CertoparinAceclofenac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Aceclofenac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Aceclofenac.Approved
CholecalciferolThe metabolism of Aceclofenac can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aceclofenac.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Aceclofenac.Approved
CinoxacinAceclofenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidAceclofenac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Aceclofenac.Vet Approved
CloranololAceclofenac may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Aceclofenac can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Aceclofenac can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Aceclofenac.Experimental
CyclosporineAceclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with D-Limonene.Investigational
Dabigatran etexilateAceclofenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Aceclofenac can be decreased when it is combined with Dabrafenib.Approved
DalteparinAceclofenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAceclofenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAceclofenac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinAceclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Aceclofenac.Experimental
DelavirdineThe metabolism of Aceclofenac can be decreased when combined with Delavirdine.Approved
DesirudinAceclofenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Aceclofenac.Approved, Investigational
DextranAceclofenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Aceclofenac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Aceclofenac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Aceclofenac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinAceclofenac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Aceclofenac.Approved, Vet Approved
DicoumarolAceclofenac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aceclofenac.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Aceclofenac.Approved
DihydrostreptomycinAceclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Aceclofenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Aceclofenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Aceclofenac.Approved
DosulepinThe metabolism of Aceclofenac can be decreased when combined with Dosulepin.Approved
DoxorubicinAceclofenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneAceclofenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Aceclofenac is combined with E-6201.Investigational
Edetic AcidAceclofenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAceclofenac may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Aceclofenac can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Aceclofenac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Aceclofenac.Approved
EnoxacinAceclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAceclofenac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Aceclofenac.Experimental
EpanololAceclofenac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Epirizole.Approved
EpirubicinAceclofenac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAceclofenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aceclofenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Aceclofenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Equilin.Approved
EsmololAceclofenac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Estrone sulfate.Approved
Etacrynic acidAceclofenac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Aceclofenac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAceclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etofenamate.Approved, Investigational
EtravirineThe metabolism of Aceclofenac can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Aceclofenac.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aceclofenac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Aceclofenac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Feprazone.Experimental
Ferulic acidAceclofenac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Aceclofenac.Approved, Investigational
FleroxacinAceclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Aceclofenac.Approved, Withdrawn
FloxuridineThe metabolism of Aceclofenac can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with fluasterone.Investigational
FluconazoleThe metabolism of Aceclofenac can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fludrocortisone.Approved
FluindioneAceclofenac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAceclofenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Aceclofenac can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Aceclofenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aceclofenac.Approved, Investigational
FluvastatinThe metabolism of Aceclofenac can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Aceclofenac can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Aceclofenac.Approved, Nutraceutical, Vet Approved
FondaparinuxAceclofenac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAceclofenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Aceclofenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Aceclofenac.Approved
FosphenytoinThe metabolism of Aceclofenac can be increased when combined with Fosphenytoin.Approved
FramycetinAceclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAceclofenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAceclofenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAceclofenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAceclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Aceclofenac.Approved, Withdrawn
GemfibrozilThe metabolism of Aceclofenac can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAceclofenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAceclofenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAceclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAceclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Aceclofenac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinAceclofenac may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Aceclofenac is combined with HE3286.Investigational
HeparinAceclofenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Higenamine.Investigational
HydralazineAceclofenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aceclofenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
Hygromycin BAceclofenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Aceclofenac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Aceclofenac.Approved
IdarubicinAceclofenac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxAceclofenac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Aceclofenac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Aceclofenac.Approved
IndenololAceclofenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Aceclofenac can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Indoprofen.Withdrawn
INNO-206Aceclofenac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Aceclofenac can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinAceclofenac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Istaroxime.Investigational
KanamycinAceclofenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Aceclofenac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Aceclofenac.Approved
LabetalolAceclofenac may decrease the antihypertensive activities of Labetalol.Approved
LandiololAceclofenac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Aceclofenac.Investigational
LeflunomideThe metabolism of Aceclofenac can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinAceclofenac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAceclofenac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololAceclofenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAceclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Aceclofenac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Aceclofenac.Approved
LobeglitazoneThe metabolism of Aceclofenac can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aceclofenac.Approved, Investigational
LosartanThe metabolism of Aceclofenac can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Aceclofenac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Aceclofenac.Approved, Investigational
LumacaftorThe serum concentration of Aceclofenac can be decreased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Aceclofenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac.Approved
ManidipineThe metabolism of Aceclofenac can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aceclofenac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Aceclofenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aceclofenac.Approved
MelagatranAceclofenac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aceclofenac.Approved, Vet Approved
MepindololAceclofenac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineAceclofenac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Aceclofenac.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Aceclofenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAceclofenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac.Approved
MetoprololAceclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideAceclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinAceclofenac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Aceclofenac can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Aceclofenac can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Aceclofenac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Aceclofenac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Aceclofenac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Aceclofenac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.Approved
NadololAceclofenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAceclofenac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAceclofenac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Aceclofenac.Approved
Nalidixic AcidAceclofenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Aceclofenac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Aceclofenac is combined with NCX 1022.Investigational
NeamineAceclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinAceclofenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAceclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nepafenac.Approved
NetilmicinAceclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Aceclofenac can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aceclofenac.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aceclofenac.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nitroaspirin.Investigational
NorfloxacinAceclofenac may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Aceclofenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceclofenac.Approved
OlsalazineAceclofenac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Aceclofenac.Investigational
OmeprazoleThe metabolism of Aceclofenac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Orgotein.Vet Approved
OtamixabanAceclofenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aceclofenac.Approved
Oxolinic acidAceclofenac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAceclofenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aceclofenac.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Paramethasone.Approved
ParomomycinAceclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Parthenolide.Investigational
PazufloxacinAceclofenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAceclofenac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAceclofenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateAceclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Aceclofenac.Approved
PhenindioneAceclofenac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Aceclofenac can be increased when combined with Phenobarbital.Approved
PhenprocoumonAceclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aceclofenac.Approved, Vet Approved
PhenytoinThe metabolism of Aceclofenac can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aceclofenac.Approved, Investigational
PindololAceclofenac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidAceclofenac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinAceclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAceclofenac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aceclofenac.Approved, Investigational
Piromidic acidAceclofenac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aceclofenac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pirprofen.Experimental
PlazomicinAceclofenac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAceclofenac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Aceclofenac.Approved
PractololAceclofenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Aceclofenac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Aceclofenac can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Aceclofenac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Propacetamol.Approved, Investigational
PropranololAceclofenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Aceclofenac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Aceclofenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Aceclofenac.Vet Approved
Protein CAceclofenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanAceclofenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAceclofenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAceclofenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Aceclofenac.Investigational
PuromycinAceclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Aceclofenac can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Aceclofenac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Aceclofenac.Approved
QuinineThe metabolism of Aceclofenac can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Aceclofenac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Aceclofenac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.Approved, Experimental, Investigational
ReviparinAceclofenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAceclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Aceclofenac can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Aceclofenac can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Risedronate.Approved, Investigational
RivaroxabanAceclofenac may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinAceclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAceclofenac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAceclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Aceclofenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Aceclofenac.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Aceclofenac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Aceclofenac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Aceclofenac.Investigational
SecobarbitalThe metabolism of Aceclofenac can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Aceclofenac can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinAceclofenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAceclofenac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Aceclofenac.Approved
SorafenibThe metabolism of Aceclofenac can be decreased when combined with Sorafenib.Approved, Investigational
SotalolAceclofenac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAceclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAceclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinAceclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Aceclofenac.Approved
SpironolactoneAceclofenac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Aceclofenac.Investigational
StreptomycinAceclofenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAceclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Aceclofenac can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Aceclofenac can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aceclofenac.Approved
SulfisoxazoleThe metabolism of Aceclofenac can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Aceclofenac.Approved
SulodexideAceclofenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Aceclofenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Aceclofenac.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Suxibuzone.Experimental
TacrolimusAceclofenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Aceclofenac.Approved
TalinololAceclofenac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Aceclofenac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Aceclofenac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Aceclofenac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Aceclofenac.Approved, Investigational
TemafloxacinAceclofenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Aceclofenac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aceclofenac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Teriflunomide.Approved
TertatololAceclofenac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aceclofenac.Approved
TicagrelorThe metabolism of Aceclofenac can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Aceclofenac can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAceclofenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tixocortol.Approved
TobramycinAceclofenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Aceclofenac can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aceclofenac.Approved
TopiroxostatThe metabolism of Aceclofenac can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideAceclofenac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Aceclofenac.Approved
TranilastThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aceclofenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aceclofenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAceclofenac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Aceclofenac.Approved, Vet Approved
TrimethoprimThe metabolism of Aceclofenac can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Triptolide.Investigational
TrovafloxacinAceclofenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAceclofenac may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Aceclofenac.Approved
Valproic AcidThe metabolism of Aceclofenac can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinAceclofenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Aceclofenac can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Aceclofenac.Approved
VoriconazoleThe metabolism of Aceclofenac can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinAceclofenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAceclofenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Aceclofenac can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Aceclofenac.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Aceclofenac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aceclofenac.Withdrawn
Zoptarelin doxorubicinAceclofenac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAceclofenac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Raza K, Kumar M, Kumar P, Malik R, Sharma G, Kaur M, Katare OP: Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems. Biomed Res Int. 2014;2014:406731. doi: 10.1155/2014/406731. Epub 2014 Jun 18. [PubMed:25045671]
  2. Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. [PubMed:15163279]
  3. Pareek A, Chandurkar N: Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013 Jul;29(7):849-59. doi: 10.1185/03007995.2013.795139. Epub 2013 Apr 30. [PubMed:23581533]
  4. Moore RA, Derry S, McQuay HJ: Single dose oral aceclofenac for postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007588. doi: 10.1002/14651858.CD007588.pub2. [PubMed:19588436]
  5. Pareek A, Chandurkar N, Gupta A, Sirsikar A, Dalal B, Jesalpura B, Mehrotra A, Mukherjee A: Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain. 2011 May;12(5):546-53. doi: 10.1016/j.jpain.2010.10.013. Epub 2011 Feb 1. [PubMed:21277837]
  6. Brogden RN, Wiseman LR: Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs. 1996 Jul;52(1):113-24. [PubMed:8799688]
  7. Dooley M, Spencer CM, Dunn CJ: Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. [PubMed:11511027]
  8. Gonzalez-Alvaro I, Carmona L, Diaz-Gonzalez F, Gonzalez-Amaro R, Mollinedo F, Sanchez-Madrid F, Laffon A, Garcia-Vicuna R: Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol. 1996 Apr;23(4):723-9. [PubMed:8730134]
  9. Ghosh S, Barik BB: A Comparative Study of the Pharmacokinetics of Conventional and Sustained-release Tablet Formulations of Aceclofenac in Healthy Male Subjects Tropical Journal of Pharmaceutical Research. 2010 September 1;9(4):395-399.
  10. Dahiya S, Kaushik A, Pathak K: Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-beta-Cyclodextrin. Sci Pharm. 2015 Feb 2;83(3):501-10. doi: 10.3797/scipharm.1509-07. Print 2015 Jul-Sep. [PubMed:26839834]
  11. UK Medicines and Healthcare products Regulatory Agency: ACECLOFENAC 100MG TABLETS product information [Link]
  12. DailyMed: CLANZA CR- aceclofenac tablet, film coated [Link]
External Links
KEGG Drug
D01545
PubChem Compound
71771
PubChem Substance
347827785
ChemSpider
64809
BindingDB
50109016
ChEBI
31159
ChEMBL
CHEMBL93645
PharmGKB
PA166049185
Wikipedia
Aceclofenac
ATC Codes
M01AB16 — AceclofenacM02AA25 — Aceclofenac
MSDS
Download (45.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Enrolling by InvitationTreatmentHealthy Volunteers1
2, 3CompletedPreventionIrreversible Pulpitis1
2, 3CompletedPreventionSymptomatic Irreversible Pulpitis1
3CompletedTreatmentDisorder of Urinary Stent1
4CompletedPreventionNSAID-associated Gastroduodenal Injury1
4CompletedTreatmentSynovitis of osteoarthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-153MSDS
water solubilityInsoluble Wikipedia
logP2.170Dahiya S, Kaushik A, and Pathak K, 2015
Predicted Properties
PropertyValueSource
Water Solubility0.00199 mg/mLALOGPS
logP4.88ALOGPS
logP3.88ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.44ChemAxon
pKa (Strongest Basic)-2.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.63 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.32 m3·mol-1ChemAxon
Polarizability32.76 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0094000000-f8c3fec999613f33dcf4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0090000000-4e970fdc8b34b418dfb4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-4ea83e6670ee0480c3f0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-5eed5bf9db2e212a1e81
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-3024a6130ab2a3ec552a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03xr-2390000000-7e1719951982f5715ecd

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aniline and substituted anilines / Dicarboxylic acids and derivatives / Aryl chlorides / Carboxylic acid esters / Amino acids / Secondary amines / Carboxylic acids / Organopnictogen compounds / Organochlorides / Organic oxides
show 2 more
Substituents
Aniline or substituted anilines / 1,3-dichlorobenzene / Aryl chloride / Aryl halide / Dicarboxylic acid or derivatives / Amino acid or derivatives / Amino acid / Carboxylic acid ester / Carboxylic acid derivative / Secondary amine
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid, carboxylic ester, secondary amino compound, dichlorobenzene, amino acid (CHEBI:31159)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. [PubMed:15163279]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. [PubMed:15163279]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on August 31, 2010 14:49 / Updated on November 09, 2017 03:55